Overview

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Status:
Not yet recruiting
Trial end date:
2027-07-02
Target enrollment:
Participant gender:
Summary
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S